233 related articles for article (PubMed ID: 6347997)
1. The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation.
Weick JK; Antunez A; Kraus TA; Fabian CJ; Dixon D
Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1205-7. PubMed ID: 6347997
[TBL] [Abstract][Full Text] [Related]
2. NHL-3 protocol. Six-drug combination chemotherapy for non-Hodgkin's lymphoma.
Koziner B; Sklaroff R; Little C; Labriola D; Thaler HT; Straus DJ; Young CW; Nisce LZ; Oettgen H; Lee BJ
Cancer; 1984 Jun; 53(12):2592-600. PubMed ID: 6547072
[TBL] [Abstract][Full Text] [Related]
3. Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). An effective, schedule-dependent treatment for advanced diffuse histiocytic lymphoma.
Johnson GJ; Costello WG; Oken MM; Sponzo RW; Barnes JM; Ezdinli EZ; Bennett JM; Silverstein MN; Glick JH; Berard CW
Cancer; 1983 Oct; 52(7):1133-41. PubMed ID: 6192894
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) for non-Hodgkin's lymphomas with unfavorable histology: preliminary results.
Comella P; Abate G; Comella G; Bruni GS; Zarrilli D; Pergola M
Tumori; 1980 Dec; 66(6):749-56. PubMed ID: 7233568
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
Elias L; Portlock CS; Rosenberg SA
Cancer; 1978 Oct; 42(4):1705-10. PubMed ID: 361209
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
Canellos GP; Skarin AT; Rosenthal DS; Moloney WC; Frei E
Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118
[TBL] [Abstract][Full Text] [Related]
7. [Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].
Sampi K; Honda T; Hattori M; Takayama S
Gan To Kagaku Ryoho; 1983 May; 10(5):1266-71. PubMed ID: 6191677
[TBL] [Abstract][Full Text] [Related]
8. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
[TBL] [Abstract][Full Text] [Related]
10. Multimodality therapy of favorable prognosis non-Hodgkin's lymphoma.
Corder MP; Leimert JT; Tewfik HH; Lovett JM
Int J Radiat Oncol Biol Phys; 1983 Jul; 9(7):1009-12. PubMed ID: 6345487
[TBL] [Abstract][Full Text] [Related]
11. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
[TBL] [Abstract][Full Text] [Related]
12. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
[TBL] [Abstract][Full Text] [Related]
14. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
15. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
Armitage JO; Dick FR; Corder MP; Garneau SC; Platz CE; Slymen DJ
Cancer; 1982 Nov; 50(9):1695-702. PubMed ID: 6749279
[TBL] [Abstract][Full Text] [Related]
16. Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas.
Harrison DT; Neiman PE; Sullivan K; Hafermann M; Rudolph RH; Einstein AB
Cancer; 1978 Oct; 42(4):1697-704. PubMed ID: 361208
[TBL] [Abstract][Full Text] [Related]
17. Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy.
Armitage JO; Corder MP; Leimert JT; Dick FR; Elliot TE
Cancer Treat Rep; 1980; 64(4-5):649-54. PubMed ID: 7000347
[TBL] [Abstract][Full Text] [Related]
18. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study.
Jones SE; Grozea PN; Metz EN; Haut A; Stephens RL; Morrison FS; Butler JJ; Byrne GE; Moon TE; Fisher R; Haskins CL; Coltman CA
Cancer; 1979 Feb; 43(2):417-25. PubMed ID: 84706
[TBL] [Abstract][Full Text] [Related]
19. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
20. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
Laver JH; Mahmoud H; Pick TE; Hutchison RE; Weinstein HJ; Schwenn M; Weitzman S; Murphy SB; Ochoa S; Shuster JJ
Leuk Lymphoma; 2002 Jan; 43(1):105-9. PubMed ID: 11908712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
